These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9723101)

  • 21. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J; Ye P
    Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW; Ose L; Marais AD
    J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hyperlipidemia in children and adolescents: diagnosis and therapy].
    Koletzko B; Herzog M
    Schweiz Med Wochenschr; 1998 Mar; 128(13):477-85. PubMed ID: 9583098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
    Hernández C; Lecube A; Barberá G; Chacón P; Lima J; Simó R
    Med Sci Monit; 2003 Mar; 9(3):CR114-9. PubMed ID: 12640339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacology of hypolipidemic agents].
    Féry F; Balasse EO
    Rev Med Brux; 1997 Feb; 18(1):26-31. PubMed ID: 9132914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
    Alcocer L; Fernández L; Campos E; Más R
    Int J Tissue React; 1999; 21(3):85-92. PubMed ID: 10645516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Which hypocholesteremic agents for which hypercholesterolemias?].
    Dairou F
    Ann Cardiol Angeiol (Paris); 1990 Dec; 39(10):591-5. PubMed ID: 2291611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in pharmacologic treatment of hyperlipidemia.
    Crouse JR; Ryu JE; Kahl FR
    Am J Prev Med; 1989; 5(2):90-4. PubMed ID: 2730796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term bezafibrate treatment in a lipid clinic].
    Yeshurun D; Abukarshin R; Ellias N; Naschitz JE
    Harefuah; 1992 May; 122(10):632-4, 687. PubMed ID: 1526540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.